- Home
- IMUX vs INVE Comparison
IMUX vs INVE Comparison
Compare IMUX & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- INVE
- Stock Information
- Founded
- IMUX 2016
- INVE 1990
- Country
- IMUX United States
- INVE United States
- Employees
- IMUX N/A
- INVE N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- INVE Computer peripheral equipment
- Sector
- IMUX Health Care
- INVE Technology
- Exchange
- IMUX Nasdaq
- INVE Nasdaq
- Market Cap
- IMUX 92.2M
- INVE 85.9M
- IPO Year
- IMUX N/A
- INVE 1997
- Fundamental
- Price
- IMUX $0.84
- INVE $3.86
- Analyst Decision
- IMUX Strong Buy
- INVE Strong Buy
- Analyst Count
- IMUX 5
- INVE 2
- Target Price
- IMUX $7.00
- INVE $5.50
- AVG Volume (30 Days)
- IMUX 1.7M
- INVE 29.3K
- Earning Date
- IMUX 11-06-2025
- INVE 11-06-2025
- Dividend Yield
- IMUX N/A
- INVE N/A
- EPS Growth
- IMUX N/A
- INVE N/A
- EPS
- IMUX N/A
- INVE 3.12
- Revenue
- IMUX N/A
- INVE $23,538,000.00
- Revenue This Year
- IMUX N/A
- INVE N/A
- Revenue Next Year
- IMUX N/A
- INVE $9.06
- P/E Ratio
- IMUX N/A
- INVE $1.24
- Revenue Growth
- IMUX N/A
- INVE N/A
- 52 Week Low
- IMUX $0.56
- INVE $2.86
- 52 Week High
- IMUX $1.73
- INVE $4.29
- Technical
- Relative Strength Index (RSI)
- IMUX 45.66
- INVE 58.92
- Support Level
- IMUX $0.78
- INVE $3.43
- Resistance Level
- IMUX $0.93
- INVE $3.81
- Average True Range (ATR)
- IMUX 0.06
- INVE 0.16
- MACD
- IMUX -0.01
- INVE 0.02
- Stochastic Oscillator
- IMUX 26.35
- INVE 85.71
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.